A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate Improvement of Symptoms of RLS in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms Who Take OXN PR Compared to Subjects Taking Placebo (PLA).

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate Improvement of Symptoms of RLS in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms Who Take OXN PR Compared to Subjects Taking Placebo (PLA).

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Oxycodone/naloxone (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 11 Jul 2016 Results of secondary efficacy variables published in the CNS Drugs
    • 07 Jul 2012 Napp Pharmaceutical Group added as associations as reported in the European Clinical Trials Database record.
    • 17 May 2012 Additional location (Sweden) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top